Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib in recurrent or persistent uterine serous carcinoma
NCT04814108Phase 2Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of azenosertib in uterine serous carcinoma (USC), sponsored by Zentalis Pharmaceuticals. Started Jul 2021; status: completed.
02
Drugs
azenosertib
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT04814108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814108.